65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02234934 (ClinicalTrials.gov) | October 29, 2015 | 4/9/2014 | Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease | A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease | Granulomatous Disease, Chronic, X-linked | Biological: Lentiviral G1XCGD Gene Therapy | University of California, Los Angeles | Boston Children's Hospital;National Heart, Lung, and Blood Institute (NHLBI);Genethon;California Institute for Regenerative Medicine (CIRM) | Recruiting | 23 Months | N/A | Male | 16 | Phase 1/Phase 2 | United States |